Lookback: How Niva Bupa Health IPO Traded on Listing Day

The Anchor Book: A Tale of Two Halves

The anchor book closed on October 31, 2024 with Rs 990 crore raised from 33 investors at Rs 320, the upper end of the band. The allocation was roughly 45% of the Rs 2,200 crore fresh issue, a strong institutional signal at the pricing stage. Domestic mutual funds dominated, absorbing over 60% of the anchor portion. SBI, HDFC, ICICI Prudential, and Kotak Mahindra each took Rs 80 crore to Rs 120 crore. Foreign portfolio investors including Capital Group, Fidelity, and Abu Dhabi Investment Authority accounted for roughly 25%, with domestic insurers and alternative investment funds filling the rest.

The pedigree was strong, but the composition told a quieter story. Some prominent long-only foreign funds that had backed Star Health and ICICI Lombard sat this one out. The eventual allocation pattern compounded the gap. Retail received 45% of the net offer, a deliberate broad-basing choice that introduced structural vulnerability since retail had no lock-in. QIBs excluding anchor took only 15%, HNIs took 15%, and the anchor book itself accounted for the remaining 25%. A large share of the day-one tradable float sat in retail hands.

Anchor investors were bound by a 30-day lock-in and could not provide secondary-market support beyond a signalling role. The anchor book validated price. It did not anchor demand.

Subscription Momentum: Reading the Tea Leaves

The book ran from November 7 to November 11, 2024 and closed at 1.85 times overall. Day one printed 0.35 times, retail at 0.60, QIB at 0.01. Day two reached 0.80 times, retail at 1.10, HNI at 0.40, QIB at 0.02. The final day delivered the customary surge: retail at 2.40 times, HNI at 1.90 times, QIB ex-anchor at 1.20 times, overall at 1.85 times.

The QIB figure was the tell. Institutions participated but did not chase. Retail at 2.40 times was healthy without exuberance. Grey market premium hovered at Rs 25 to Rs 30, implying a listing print of Rs 345 to Rs 350. IPOs subscribed below 3 times historically deliver single-digit to low-teens listing gains. The 9.37% open landed inside that band.

Retail applications skewed heavily toward Gujarat and Rajasthan, both states with quick-flip trading cultures. The HNI book was leveraged on borrowed funds, adding interest-cost pressure to exit on day one.

The Debut Session: Anatomy of a Fizzle

Caption: NIVABUPA weekly timeframe around 2024-11-14.

The NSE open was Rs 350, a 9.37% premium. BSE opened at Rs 349.50 and converged quickly. The stock printed an intraday high of Rs 355 inside the first ten minutes as algorithmic traders and late buyers pushed it up. That was the zenith. By the end of the first hour the price sat at Rs 335, down 4.3% from the open and only 4.7% above issue. Opening-hour volume exceeded 8 million shares, roughly 15% of non-anchor allotment.

The volume-weighted average price settled at Rs 338.20. The close was Rs 332.50, down 5% from the open and 3.9% above issue. Total volume was 18.5 million shares, around Rs 625 crore in turnover. Delivery was a low 28%, confirming intraday speculation dominated the tape.

Retail allottees sitting on a 9% gain at Rs 320 cost sold relentlessly. QIB participation at 1.20 times did not translate into open-market accumulation. Anchors were locked. The order book was one-sided.

At Rs 350, Niva Bupa traded at roughly 4.8 times post-issue book. Star Health stood near 3.5 times; ICICI Lombard above 6 times. The combined ratio sat above 100%, and the company had posted a net loss in the prior fiscal. Institutions waited.

The 30-Day Price Discovery: A Slow Bleed

Caption: NIVABUPA daily timeframe around 2024-11-14.

November 15 opened at Rs 330 and closed at Rs 325, down 2.3%, on 12 million shares. The stock briefly stabilised near the Rs 320 issue price in the third week of November as value buyers tested the level. Support broke on November 22 when it closed at Rs 315.

The final week of November accelerated lower as bond yields rose and risk appetite faded. The stock touched Rs 298 on November 28, down 6.9% from issue and 14.9% from the listing-day open. The selling was a steady drip rather than a flush, partly retail and partly leveraged HNIs facing margin pressure. Daily RSI dipped below 30 repeatedly without producing meaningful bounces. The 20-day moving average capped each recovery attempt. By December 14 the stock settled at Rs 305, down 4.7% from issue.

Bulk-deal and delivery data identified the buyers. HDFC Mutual Fund accumulated additional shares in the open market in late November. SBI Mutual Fund and ICICI Prudential Mutual Fund were net buyers through the window in modest size. Retail and HNI registers shrank. The float rotated from weak hands to institutional ones.

The anchor lock-in expired on December 13, 2024. The stock edged to Rs 312 on the day and settled at Rs 305 on December 14. There was no liquidation. The overhang resolved cleanly, which itself was a signal of confidence.

Sectoral Context: The Peer Pressure

Star Health fell 12% over the same window, from Rs 580 to Rs 510, on a soft September quarter and rising claims ratios. ICICI Lombard fell 5%, from Rs 1,420 to Rs 1,349. The Nifty 50 was down 2%. The health insurance complex underperformed the index, and Niva Bupa was tethered to that drag.

At the Rs 320 issue price, market capitalisation was roughly Rs 12,800 crore, a price-to-book of 4.4 times on post-issue net worth. The number sat between Star Health at 3.5 times and ICICI Lombard at 6.2 times. The premium to Star Health was justified by faster growth and the Bupa brand association. The discount to ICICI Lombard reflected smaller scale, single-line concentration, and underwriting losses. By December 14 the multiple compressed to about 4.0 times.

Brokerage initiations were split. Motilal Oswal opened Neutral at Rs 340. ICICI Securities went Buy at Rs 380, arguing the post-listing drop created an entry point. HDFC Securities went Reduce at Rs 290 on combined-ratio concerns. Average target across the five major initiations was Rs 330.

Historical context: Star Health listed in December 2021 at a 6% discount to its Rs 900 issue and fell to Rs 480 by December 2022, down 47%. ICICI Lombard listed in September 2017 at a 1% premium to Rs 661 and reached Rs 1,200 by September 2019. Niva Bupa sat between these arcs.

The Charts: A Visual Narrative

Caption: NIVABUPA 30min timeframe around 2024-11-14.

The weekly chart shows the stock listing near its opening level and drifting lower, with the 20-period EMA acting as dynamic resistance throughout the decline. Volume peaked in the listing week and faded.

The daily chart, with 20, 50, and 200-day moving averages alongside volume and RSI, shows oversold readings that failed to produce trend-reversing bounces. The 20-day crossed below the 50-day in early December, a clean bearish trigger that confirmed the short-term downtrend.

The 30-minute intraday print for listing day shows VWAP at Rs 338.20 below the open, a volume spike in the first thirty minutes, and recurring volume bursts on downward ticks. Textbook open-and-fade.

VERDICT

Stance: NEUTRAL with a cautious bias Horizon: 1-month (January 14, 2025) and 3-month (March 14, 2025)

The 4.7% decline from issue and 12.9% drop from the listing-day open place the stock in a balanced zone. It has trailed the Nifty 50 by 2.7 percentage points but tracked closely with Star Health, which fell 12%. At a price-to-book of 4.0 times on the December 14 close, valuation is no longer demanding. Domestic mutual fund accumulation at lower levels suggests a floor is forming. Near-term headwinds, including residual anchor selling risk, sector dynamics, and the absence of a clear earnings catalyst, argue against an aggressive bullish posture.

One-month range: Rs 290 to Rs 330. A close above Rs 330 on sustained volume turns the structure bullish; a break below Rs 290 signals deeper structural issues. The three-month path hinges on the December quarter print, expected February 2025. Combined-ratio improvement and a credible path to underwriting profit could re-rate the stock toward Rs 350. A miss drags it toward Rs 270, roughly 3.5 times book, in line with Star Health. The setup demands patience and a close read of fundamentals, not aggression.